Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
Xiaofei Xin, Virender Kumar, Feng Lin, Vinod Kumar, Rajan Sharma Bhattarai, Vijaya Raj Bhatt, Chalet Tan, Ram I. Mahato
Abstract
-methyl phosphorothioate (OMe-PS) at 3' end enhanced its stability and activity without being immunogenic. Epidermal growth factor receptor targeting peptide GE11 decoration increased tumor accumulation of micelles after systemic administration and significantly inhibited orthotopic desmoplastic pancreatic cancer growth in NSG mice by down-regulating HIF-1α and genes responsible for glucose uptake and cancer cell metabolism. Our multifunctional nanomedicine of GEM and OMe-PS-miR-519c offers a novel therapeutic strategy to treat desmoplasia and hypoxia-induced chemoresistance in pancreatic cancer.
Topics & Concepts
GemcitabinePancreatic cancerCancer researchDesmoplasiaChemistryEpidermal growth factor receptorHypoxia (environmental)TransfectionmicroRNACancer cellCancerMedicineInternal medicineBiochemistryGeneOxygenOrganic chemistryCancer, Hypoxia, and MetabolismNanoplatforms for cancer theranosticsMicroRNA in disease regulation